Seer Files ITC Complaint Against Nanomics

Rhea-AI Summary

Argus May 29 session

-3.11% close to close Open Argus

Details

News Market Reaction – SEER

On May 29, the day this news came out, SEER closed 3.11% below the previous close.

Data tracked by StockTitan Argus for the May 29 session.

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   AI/proteomics showcase

   24h Move

   +1.1%

   Planned showcase of AI-driven screening and next-gen proteomics tools at ASMS 2026.

2. May 21

   Bid rejection

   24h Move

   +1.1%

   Board unanimously rejected Radoff-JEC offer at $2.40 plus CVR as undervaluing Seer.

3. May 14

   Acquisition proposal

   24h Move

   -1.1%

   Radoff-JEC Group submitted third non-binding proposal to acquire Seer.

4. May 13

   Q1 2026 earnings

   24h Move

   -1.1%

   Reported revenue decline, ongoing net loss, but reaffirmed 2026 revenue outlook.

5. May 13

   Patent lawsuit

   24h Move

   -2.8%

   Filed patent infringement lawsuit against Nanomics to protect IP position.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

international trade commission, exclusion order, patent infringement, intellectual property, +2 more

6 terms

international trade commission regulatory

"filed a complaint at the United States International Trade Commission (ITC) against Nanomics"

A government body that acts like a referee for cross-border commerce, reviewing complaints about unfair practices, banned imports, tariffs or patent violations and issuing rulings or penalties. Its decisions can quickly change which foreign products can be sold, add costs through duties or block imports entirely, so investors watch rulings for sudden impacts on a company’s sales, supply chains, profit margins and competitive position.

exclusion order regulatory

"Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations"

An exclusion order is a government directive that bars specific products from entering or being sold in a market because they violate laws or regulations, most often intellectual property or import rules. For investors, it matters because it can suddenly cut a company’s sales or remove competitors’ products from shelves—like a referee stopping a player from rejoining a game, it changes who can compete and where revenue can flow.

patent infringement regulatory

"The ITC complaint builds on the patent infringement suit filed in federal district court"

Patent infringement occurs when someone makes, uses, sells or imports a product or process that is covered by another party’s patent without permission — like copying a chef’s secret recipe and selling the dish without consent. For investors it matters because alleged infringement can trigger costly lawsuits, damage awards, sales bans or forced licensing, any of which can reduce revenue, increase expenses and hurt a company’s stock value.

intellectual property regulatory

"which protect Seer's intellectual property in the field of nanoparticle protein enrichment"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

proteomics medical

"deep, unbiased proteomic insights, today announced that it has filed a complaint"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

nanoparticle protein enrichment medical

"protect Seer's intellectual property in the field of nanoparticle protein enrichment"

A laboratory method that uses tiny engineered particles to capture and concentrate specific proteins from a complex sample, like blood or saliva, so they are easier to detect and analyze. Think of it like casting a small net that pulls out rare fish from a large pond: by boosting the signal and reducing background noise, the technique can make diagnostics, biomarker discovery, and quality control faster, more reliable and potentially less expensive, which matters to investors evaluating product potential, market adoption and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations

REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a complaint at the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd. The Brigham and Women's Hospital has joined the ITC complaint as well.

The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC complaint seeks institution of an investigation into Nanomics' importation and sale of its Proteonano kits and workstations, and an exclusion order barring those products from entering the United States.

"Seer pioneered the technology and advanced the science that makes it possible to pursue deep, unbiased proteomics at scale, catalyzing large data sets that will drive AI-enabled biological discoveries. We have an obligation to ensure that this technology delivers the most robust and reproducible data for our customers," said Omid Farokhzad, Chair and Chief Executive Officer of Seer. "Filing this ITC complaint, alongside our district court action, reflects our resolve to use every available avenue to protect our technology, innovations, and product integrity that have defined this field and that our customers rely on every day."

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to overcome the throughput and complexity limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s proprietary technology and products and any third-party infringement thereof. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio